Incyte is strategically investing in artificial intelligence for R&D, highlighted by a new collaboration with Genesis Molecular AI in May 2026. This initiative creates needs for supporting data infrastructure, cloud computing, and AI governance tools to manage the risks of inaccurate analyses and data security.
Filing excerpt
The use of artificial intelligence is increasing in the biopharmaceutical industry for research, marketing, manufacturing and commercialization purposes, and we anticipate increasing our use of technology that incorporates artificial intelligence in the future.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Vendors
sec-10qjointVentureGet every 10-Q signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/2d78ca9a-1773-4a9f-a7df-8f25019121e4 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "2d78ca9a-1773-4a9f-a7df-8f25019121e4",
"signal_type": "sec-10q",
"signal_subtype": "jointVenture",
"detected_at": "2026-08-04T07:07:36.31+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "Incyte is strategically investing in artificial intelligence for R&D, highlighted by a new collaboration with Genesis Molecular AI in May 2026. This initiative creates needs for supporting data infrastructure, cloud computing, and AI governance tools to manage the risks of inaccurate analyses and data security.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Upfront payment, equity investment, and potential milestone payments for Genesis Molecular AI collaboration."
},
"summary": "Incyte forms AI collaboration with Genesis Molecular AI to accelerate drug discovery.",
"excerpts": "The use of artificial intelligence is increasing in the biopharmaceutical industry for research, marketing, manufacturing and commercialization purposes, and we anticipate increasing our use of technology that incorporates artificial intelligence in the future.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm",
"filing_date": "2026-07-28",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"vendors_mentioned": [
"Genesis Molecular AI"
],
"technologies_mentioned": [
"Artificial Intelligence"
]
}
}
curl https://signals.autobound.ai/v1/signals/2d78ca9a-1773-4a9f-a7df-8f25019121e4 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.